title: Nucleolar disruption leads to the spatial separation of key 18S rRNA processing factors.
abstract: Many chemotherapeutic drugs cause the downregulation of ribosome production and the disruption of nucleolar function. This stabilizes p53 and leads to either cell cycle arrest or apoptosis. It is not clear, however, how these agents cause nucleolar disruption and block ribosome production. The small subunit (SSU) processome, which has been primarily studied in yeast, is responsible for the processing of the 18S rRNA and assembly of the small ribosomal subunit. Here we have characterized the human homologs of seven SSU processome components. Furthermore, we have investigated the effects of three chemotherapeutic drugs, Actinomycin D (ActD), camptothecin (CPT) and 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) on the subcellular distribution of key SSU processome components and the formation of this processing complex. Interestingly, ActD- and DRB-treatment resulted in the majority of U3 small nucleolar RNP (snoRNP) localizing separately to other key components of the SSU processome. All three agents affected RNA polymerase I transcription, primarily at the level of elongation but only ActD resulted in a clear reduction in SSU processome levels. Taken together, our data indicate that different chemotherapeutic agents, each of which initiates a stress response and cause nucleolar disruption, have different effects on the formation and localization of the SSU processome.
authors.affiliation: Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne, UK.
authors.forename: Amy Jane
authors.initials: AJ
authors.lastname: Turner
authors.forename: Andrew Alexander
authors.initials: AA
authors.lastname: Knox
authors.forename: Nicholas James
authors.initials: NJ
authors.lastname: Watkins
mesh_terms: D002166:Camptothecin / Q000494:pharmacology; D002466:Cell Nucleolus / Q000187:drug effects / Q000378:metabolism*; D003609:Dactinomycin / Q000494:pharmacology; D004004:Dichlororibofuranosylbenzimidazole / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D009687:Nuclear Proteins / Q000378:metabolism; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D021381:Protein Transport / Q000187:drug effects; D012318:RNA Polymerase I / Q000378:metabolism; D012337:RNA, Ribosomal, 18S / Q000378:metabolism*; D020718:Ribonucleoproteins, Small Nucleolar / Q000378:metabolism; D059004:Topoisomerase I Inhibitors / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D009687:Nuclear Proteins; D019384:Nucleic Acid Synthesis Inhibitors; D011500:Protein Synthesis Inhibitors; D012337:RNA, Ribosomal, 18S; D020718:Ribonucleoproteins, Small Nucleolar; D059004:Topoisomerase I Inhibitors; D003609:Dactinomycin; D004004:Dichlororibofuranosylbenzimidazole; D012318:RNA Polymerase I; D002166:Camptothecin